Scilex Holding (SCLXW) Cash & Equivalents (2020 - 2026)
Scilex Holding (SCLXW) recorded quarterly Cash & Equivalents of $144.9 million in Q1 2026, up 2823.77% quarter-over-quarter from $5.0 million in Q4 2025, and up 2397.81% on a YoY basis from $5.8 million in Q1 2025.
Scilex Holding (SCLXW) Cash & Equivalents (2020 - 2026) Analysis & Trends
Scilex Holding's Cash & Equivalents history runs 7 years deep, the most recent figure standing at $144.9 million for Q1 2026.
- In Q1 2026, Cash & Equivalents rose 2397.81% year-over-year to $144.9 million; the TTM figure through Mar 2026 stood at $144.9 million (up 2397.81% YoY), while the FY2025 annual figure was $5.0 million, up 51.44% from the prior year.
- Cash & Equivalents was $144.9 million for Q1 2026 at Scilex Holding, up from $5.0 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $144.9 million in Q1 2026 to a low of $34961.0 in Q3 2022.
- Historically, Cash & Equivalents has averaged $13.0 million across 5 years, with a median of $3.3 million in 2024.
- The sharpest annual moves came in 2023 and 2024: Cash & Equivalents soared 9613.84% in 2023, then slumped 96.15% in 2024.
- A 5-year view of Cash & Equivalents shows it stood at $2.2 million in 2022, then surged by 79.53% to $3.9 million in 2023, then dropped by 16.55% to $3.3 million in 2024, then soared by 51.44% to $5.0 million in 2025, then soared by 2823.77% to $144.9 million in 2026.
- The last three Cash & Equivalents figures came in at $144.9 million (Q1 2026), $5.0 million (Q4 2025), and $900000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 4.64 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 5.28 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 21.69 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 9.39 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 5.33 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 12.04 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 7.63 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 1.70 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 9.57 Bn |
| 10 | Scilex Holding | - | - | 4.15 Mn | 144.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 144.87 Mn |
| Dec 31, 2025 | 4.96 Mn |
| Sep 30, 2025 | 900,000.00 |
| Jun 30, 2025 | 4.10 Mn |
| Mar 31, 2025 | 5.80 Mn |
| Dec 31, 2024 | 3.27 Mn |
| Sep 30, 2024 | 77,000.00 |
| Jun 30, 2024 | 6.89 Mn |
| Mar 31, 2024 | 1.82 Mn |
| Dec 31, 2023 | 3.92 Mn |
| Sep 30, 2023 | 2.00 Mn |
| Jun 30, 2023 | 34.12 Mn |
| Mar 31, 2023 | 5.10 Mn |
| Dec 31, 2022 | 2.18 Mn |
| Sep 30, 2022 | 34,961.00 |
| Jun 30, 2022 | 351,272.00 |
| Mar 31, 2022 | 127,440.00 |
| Dec 31, 2021 | 4.34 Mn |
| Sep 30, 2021 | 115,642.00 |
| Jun 30, 2021 | 257,621.00 |